Justin Chakma

Justin Chakma is a life sciences venture capital investor with Thomas, McNerney & Partners in La Jolla, CA. He has published over 20 articles in peer-reviewed journals on healthcare policy and innovation, including the New England Journal of Medicine.

Recent posts

U.S. Biomedical Research at a Precipice
[Editor’s Note: this post was co-authored by Justin Chakma, Dr. Reshma Jagsi, and Stephen M. Sammut.]
Since 1950, U.S. government funding has supported research underlying 84 percent of Nobel... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
How to Approach Life Sciences Fundraising
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
How Big Is the US Market for Medical Devices & Technologies?
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy National

Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients

BioNTech's mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity

Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data

CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy

Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

Roche Gets FDA OK for Injectable Version of Breast Cancer Drug

Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug

Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

This Week’s AI & Drug Discovery Conference Xcelerating Life Sciences San Francisco Features insitro, Atomwise, twoXAR, InterVenn, Engine Biosciences & More

Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage

Akili Interactive’s Video Game for ADHD Gets the FDA All Clear

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

The 2020 National Xconomy Awards

Xcelerating Life Sciences Seattle

Xcelerating Life Sciences New York

Justin Chakma

Recent posts

U.S. Biomedical Research at a Precipice

Underwriters and Partners

How to Approach Life Sciences Fundraising

The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace

How Big Is the US Market for Medical Devices & Technologies?

Xconomy on Demand

We offer a number of ways to subscribe for free!